These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27896112)

  • 1. Effects of intracerebroventricular administration of 2-hydroxypropyl-β-cyclodextrin in a patient with Niemann-Pick Type C disease.
    Matsuo M; Shraishi K; Wada K; Ishitsuka Y; Doi H; Maeda M; Mizoguchi T; Eto J; Mochinaga S; Arima H; Irie T
    Mol Genet Metab Rep; 2014; 1():391-400. PubMed ID: 27896112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cyclodextrin in two patients with Niemann-Pick Type C disease.
    Matsuo M; Togawa M; Hirabaru K; Mochinaga S; Narita A; Adachi M; Egashira M; Irie T; Ohno K
    Mol Genet Metab; 2013 Jan; 108(1):76-81. PubMed ID: 23218948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial.
    Sharma R; Hastings C; Staretz-Chacham O; Raiman J; Paucar M; Spiegel R; Murray B; Hurst B; Liu B; Kjems L; Hrynkow S
    Mol Genet Metab Rep; 2023 Sep; 36():100988. PubMed ID: 37670901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracerebroventricular 2-hydroxypropyl-γ-cyclodextrin alleviates hepatic manifestations without distributing to the liver in a murine model of Niemann-Pick disease type C.
    Yamada Y; Ishitsuka Y; Fukaura-Nishizawa M; Kawata T; Ishii A; Shirakawa A; Sakai T; Tanaka M; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Seki T; Kurauchi Y; Katsuki H; Higaki K; Ikeda R; Matsuo M; Era T; Irie T
    Life Sci; 2024 Aug; 350():122776. PubMed ID: 38852794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential mode of cholesterol inclusion with 2-hydroxypropyl-cyclodextrins increases safety margin in treatment of Niemann-Pick disease type C.
    Yamada Y; Ishitsuka Y; Kondo Y; Nakahara S; Nishiyama A; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kamei S; Shuto T; Kai H; Hayashino Y; Sugita M; Kikuchi T; Hirata F; Miwa T; Takeda H; Orita Y; Seki T; Ohta T; Kurauchi Y; Katsuki H; Matsuo M; Higaki K; Ohno K; Matsumoto S; Era T; Irie T
    Br J Pharmacol; 2021 Jul; 178(13):2727-2746. PubMed ID: 33782944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro and In Vivo Evaluation of 6-O-α-Maltosyl-β-Cyclodextrin as a Potential Therapeutic Agent Against Niemann-Pick Disease Type C.
    Yasmin N; Ishitsuka Y; Fukaura M; Yamada Y; Nakahara S; Ishii A; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Okada Y; Nishikawa J; Ichikawa A; Iohara D; Hirayama F; Higaki K; Ohno K; Matsuo M; Irie T
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.
    Hastings C; Liu B; Hurst B; Cox GF; Hrynkow S
    Mol Genet Metab; 2022 Dec; 137(4):309-319. PubMed ID: 36279795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Data in Patients with Niemann-Pick Type C Disease Under Combined High Intrathecal and Low Intravenous Dose of 2-hydroxylpropyl-β-cyclodextrin.
    Bountouvi E; Giorgi M; Papadopoulou A; Blennow K; Björkhem I; Tsirouda M; Kanellakis S; Fryganas A; Spanou M; Georgaki I; Asprogeraka S; Dinopoulos A
    Innov Clin Neurosci; 2021; 18(1-3):11-16. PubMed ID: 34150357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anesthetic management of pediatric patients with Niemann-Pick disease type C for intrathecal 2-hydroxypropyl-β-cyclodextrin injection.
    Ulloa ML; Froyshteter AB; Kret LN; Chang DP; Sarah GE; McCarthy RJ; Barnes SD; Berry-Kravis EM
    Paediatr Anaesth; 2020 Jul; 30(7):766-772. PubMed ID: 32349180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Treatment of Niemann-Pick Type C1 Disease With Intrathecal 2-Hydroxypropyl-β-Cyclodextrin.
    Berry-Kravis E; Chin J; Hoffmann A; Winston A; Stoner R; LaGorio L; Friedmann K; Hernandez M; Ory DS; Porter FD; O'Keefe JA
    Pediatr Neurol; 2018 Mar; 80():24-34. PubMed ID: 29429782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal 2-hydroxypropyl-beta-cyclodextrin in a single patient with Niemann-Pick C1.
    Maarup TJ; Chen AH; Porter FD; Farhat NY; Ory DS; Sidhu R; Jiang X; Dickson PI
    Mol Genet Metab; 2015; 116(1-2):75-9. PubMed ID: 26189084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyrotaxane-based systemic delivery of β-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease.
    Tamura A; Yui N
    J Control Release; 2018 Jan; 269():148-158. PubMed ID: 29138063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanded access with intravenous hydroxypropyl-β-cyclodextrin to treat children and young adults with Niemann-Pick disease type C1: a case report analysis.
    Hastings C; Vieira C; Liu B; Bascon C; Gao C; Wang RY; Casey A; Hrynkow S
    Orphanet J Rare Dis; 2019 Oct; 14(1):228. PubMed ID: 31639011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of intrathecal cyclodextrin in patients with Niemann-Pick disease type C.
    Matsuo M; Sakakibara T; Sakiyama Y; So T; Kosuga M; Kakiuchi T; Ichinose F; Nakamura T; Ishitsuka Y; Irie T
    Brain Dev; 2024 May; 46(5):207-212. PubMed ID: 38448301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fine-tuned cholesterol solubilizer, mono-6-O-α-D-maltosyl-γ-cyclodextrin, ameliorates experimental Niemann-Pick disease type C without hearing loss.
    Yamada Y; Miwa T; Nakashima M; Shirakawa A; Ishii A; Namba N; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kurauchi Y; Seki T; Katsuki H; Okada Y; Ichikawa A; Higaki K; Hayashi K; Minami K; Yoshikawa N; Ikeda R; Ishikawa Y; Kajii T; Tachii K; Takeda H; Orita Y; Matsuo M; Irie T; Ishitsuka Y
    Biomed Pharmacother; 2022 Nov; 155():113698. PubMed ID: 36116252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the Mechanism of Cyclodextrins in the Treatment of Niemann-Pick Disease Type C Using Crosslinked 2-Hydroxypropyl-β-cyclodextrin.
    Carradori D; Chen H; Werner B; Shah AS; Leonardi C; Usuelli M; Mezzenga R; Platt F; Leroux JC
    Small; 2020 Nov; 16(46):e2004735. PubMed ID: 33079457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann-Pick C1 mutant cell via lysosome-associated membrane protein 1.
    Singhal A; Szente L; Hildreth JEK; Song B
    Cell Death Dis; 2018 Oct; 9(10):1019. PubMed ID: 30282967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases.
    Megías-Vericat JE; García-Robles A; Company-Albir MJ; Fernández-Megía MJ; Pérez-Miralles FC; López-Briz E; Casanova B; Poveda JL
    Neurol Sci; 2017 May; 38(5):727-743. PubMed ID: 28155026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of multi-lactose-appended β-cyclodextrin and its cholesterol-lowering effects in Niemann-Pick type C disease-like HepG2 cells.
    Motoyama K; Nishiyama R; Maeda Y; Higashi T; Ishitsuka Y; Kondo Y; Irie T; Era T; Arima H
    Beilstein J Org Chem; 2017; 13():10-18. PubMed ID: 28179943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pluronic based β-cyclodextrin polyrotaxanes for treatment of Niemann-Pick Type C disease.
    Collins CJ; Loren BP; Alam MS; Mondjinou Y; Skulsky JL; Chaplain CR; Haldar K; Thompson DH
    Sci Rep; 2017 Apr; 7():46737. PubMed ID: 28452365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.